Lipid nanoparticles and methods of delivering nucleic acids
A lipid nanoparticle composition with a specific ratio of cationic lipid, sterol, and PEG-modified lipids enhances liver-targeted delivery of nucleic acids, addressing off-target issues in existing LNPs.
WO2026143008A1PCT designated stage Publication Date: 2026-07-02NITTO DENKO CORP
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- NITTO DENKO CORP
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing lipid nanoparticles (LNPs) lack the ability to deliver nucleic acids preferentially to specific organs, leading to off-target effects.
Method used
A lipid nanoparticle composition comprising 55-65 mol% cationic lipid, 30-40 mol% sterol, 1-3 mol% DOPE, and 1-5 mol% DMG-PEG, with specific cationic lipids like those represented by Formulas I, II, or III, is developed to enhance targeted delivery to the liver.
Benefits of technology
The formulation achieves preferential delivery of nucleic acids to the liver, reducing off-target effects and improving therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060915_02072026_PF_FP_ABST
Abstract
A lipid nanoparticle and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may contain 55-65 mol% of a cationic lipid to the total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 1-3 mol% of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle. The lipid nanoparticle may also contain 55-65 mol% of a cationic lipid to a total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 4-6 mol% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle.
Need to check novelty before this filing date? Find Prior Art